{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000013","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.398136+00:00","generated_at":"2026-05-16T06:59:20.009641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg","bullets":["FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.","Bexobrutideg Phase 1 in r/r CLL: 83% ORR, median PFS 22.1 months; DAYBreak pivotal Phase 2 initiated at 600 mg.","Completed $250M stock offering in Oct 2025; cash, cash equivalents & marketable securities $592.9M.","Appointed Roger Dansey to Board; Phase 3 randomized trial vs pirtobrutinib expected H1 2026.","Preclinical IRAK4 degrader GS-6791 data presented; Phase 1 HV study ongoing; autoimmune IND planned 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000013","json":"https://secwatch.observer/filing/0001549595-26-000013.json","markdown":"https://secwatch.observer/filing/0001549595-26-000013.md","text":"https://secwatch.observer/filing/0001549595-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/0001549595-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/nrix-20260128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:59:20.009641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}